Fujii M, Kochi M, Mochizuki F
Dept. of Surgery III, Nihon University School of Medicine, Tokyo, Japan.
Gan To Kagaku Ryoho. 2000 Nov;27(13):2028-32.
Neoadjuvant chemotherapy for high-risk patients with advanced gastric cancer is important to increase the chance for curative resection and make unresectable gastric cancer tumors resectable by down-staging of the tumor. Tumors with H0, P0, T3, T4, or N3 are the best candidates for this therapy. Randomized controlled phase III studies are needed in conjunction with accurate staging of the disease by laparoscopy. The results of histopathologic evaluation of resected materials following preoperative chemotherapy using oral fluoropyrimidine are thought to be useful as an indicator of chemosensitivity for postoperative adjuvant setting.
对于晚期胃癌高危患者,新辅助化疗对于增加根治性切除机会以及通过肿瘤降期使不可切除的胃癌肿瘤变得可切除至关重要。具有H0、P0、T3、T4或N3的肿瘤是这种治疗的最佳候选者。需要结合腹腔镜对疾病进行准确分期开展随机对照III期研究。术前使用口服氟嘧啶化疗后切除材料的组织病理学评估结果被认为可作为术后辅助治疗化疗敏感性的指标。